Screening of undiagnosed diabetes can be performed effectively with an automatic retinal image analysis (ARIA) technology developed by researchers at the Chinese University of Hong Kong (CUHK), instead of a finger-prink test.
The combination of bamlanivimab and etesevimab reduces the risk of COVID-19-related hospitalization and any-cause death in high-risk ambulatory patients, particularly those with diabetes, according to the BLAZE-1* study presented at EASD 2021.
Treatment with a higher dose of semaglutide led to significantly improved glucose metabolism outcomes in patients with overweight/obesity and type 2 diabetes (T2D) compared with a lower dose of semaglutide or placebo, according to the STEP* 2 trial presented at EASD 2021.
The consumption of fructose from fruit juice and sugar sweetened beverages (SSBs), but not from fruit, is associated with higher intrahepatic lipid (IHL) content, according to data from a cross-sectional study presented at EASD 2021.
Older age and elevated levels of the inflammatory marker C-reactive protein (CRP) may predict mortality in COVID-19 patients, particularly if coupled with diabetes, the retrospective ACCREDIT study has shown.
A novel fully closed-loop system (fully artificial pancreas) delivering faster-acting insulin aspart (Fiasp) plus pramlintide achieved a high rate of glycaemic control among patients with type 1 diabetes (T1D) without the need for carbohydrate counting, according to a crossover noninferiority study presented at EASD 2021.
Individuals who are obese but without metabolic abnormalities (metabolically healthy obese [MHO]) have an elevated risk of developing MACE-HF*, new-onset heart failure (HF), and new-onset atrial fibrillation (AF), according to a French study presented at EASD 2021.
In individuals with type 2 diabetes (T2D), the glucagon-like peptide-1 receptor agonist (GLP1-RA) liraglutide appeared to yield a cardioprotective benefit, data from the secondary endpoint analysis of the LIRAFLAME* trial suggests.